Non-pharmacological Management of Multiple Sclerosis: A Focus on Diet and Supplementation
DOI:
https://doi.org/10.12775/QS.2025.48.67031Keywords
multiple sclerosis, Ketogenic diet, intermittent fasting, dietary supplementation, fatigue, neurodegeneration, neuroprotectionAbstract
Background: Multiple sclerosis (MS) is a chronic autoimmune and demyelinating disease of the central nervous system, characterized by inflammation, neurodegeneration, and diverse neurological symptoms. Emerging evidence suggests that dietary interventions and supplementation may influence disease activity, symptom severity, and overall quality of life in MS patients.
Objective: This review aims to present current knowledge on the effects of specific dietary patterns, caloric restriction, and nutritional supplementation on the clinical management and progression of MS.
Methods: Peer-reviewed studies published between 2015 and 2025 were identified through PubMed and Google Scholar using keywords including “multiple sclerosis,” “diet,” “ketogenic diet,” “Swank diet,” “Wahls diet,” “fasting,” “vitamin D,” and “epigallocatechin gallate.” Studies were selected based on scientific credibility, relevance, and methodological integrity.
Results: Evidence suggests that the Swank and Wahls diets, despite differing approaches, both improve fatigue, mood, and quality of life by emphasizing high fruit and vegetable intake and limiting saturated fats and processed foods. Ketogenic diet enhance mitochondrial function, reduce pro-inflammatory enzyme expression, and may support remyelination. Vitamin D supplementation demonstrates immunomodulatory and neuroprotective effects, while epigallocatechin gallate may further reduce inflammation, anxiety, and cardiovascular risk. However, limitations of these studies include small sample sizes, short study durations, and varies interventions, complicating the isolation of individual effects.
Conclusions: Dietary interventions and supplementation represent promising adjunctive strategies for MS management. While current evidence supports potential benefits in symptom reduction, neuroprotection, and quality of life, large-scale, long-term randomized controlled trials are needed to establish efficacy, safety, and underlying mechanisms.
References
[1] Rodríguez Murúa S, Farez MF, Quintana FJ. The Immune Response in Multiple Sclerosis. Annu Rev Pathol. 2022 Jan 24;17:121-139. doi: 10.1146/annurev-pathol-052920-040318 Epub 2021 Oct 4. PMID: 34606377.
[2] Haase S, Linker RA. Inflammation in multiple sclerosis. Ther Adv Neurol Disord. 2021 Apr 16;14:17562864211007687. doi: 10.1177/17562864211007687. PMID: 33948118; PMCID: PMC8053832.
[3] Patti F, Vila C. Symptoms, prevalence and impact of multiple sclerosis in younger patients: a multinational survey. Neuroepidemiology. 2014;42(4):211-8. doi: 10.1159/000360423. Epub 2014 May 7. PMID: 24821493.
[4] Tarlinton RE, Khaibullin T, Granatov E, Martynova E, Rizvanov A, Khaiboullina S. The Interaction between Viral and Environmental Risk Factors in the Pathogenesis of Multiple Sclerosis. Int J Mol Sci. 2019 Jan 14;20(2):303. doi: 10.3390/ijms20020303. PMID: 30646507; PMCID: PMC6359439.
[5] Vitturi BK, Cellerino M, Boccia D, Leray E, Correale J, Dobson R, van der Mei I, Fujihara K, Inglese M. Environmental risk factors for multiple sclerosis: a comprehensive systematic review and meta-analysis. J Neurol. 2025 Jul 15;272(8):513. doi: 10.1007/s00415-025-13248-0. PMID: 40664781; PMCID: PMC12263771.
[6] Noseworthy JH, Lucchinetti C, Rodriguez M, Weinshenker BG. Multiple sclerosis. N Engl J Med. 2000 Sep 28;343(13):938-52. doi: 10.1056/NEJM200009283431307. PMID: 11006371.
[7] Wahls TL, Chenard CA, Snetselaar LG. Review of Two Popular Eating Plans within the Multiple Sclerosis Community: Low Saturated Fat and Modified Paleolithic. Nutrients. 2019 Feb 7;11(2):352. doi: 10.3390/nu11020352 PMID: 30736445; PMCID: PMC6412750.
[8] Wahls TL, Titcomb TJ, Bisht B, Eyck PT, Rubenstein LM, Carr LJ, Darling WG, Hoth KF, Kamholz J, Snetselaar LG. Impact of the Swank and Wahls elimination dietary interventions on fatigue and quality of life in relapsing-remitting multiple sclerosis: The WAVES randomized parallel-arm clinical trial. Mult Scler J Exp Transl Clin. 2021 Jul 31;7(3):20552173211035399. doi: 10.1177/20552173211035399 PMID: 34377527; PMCID: PMC8326636.
[9] Villa AT, Tu BH, Titcomb TJ, Saxby SM, Shemirani F, Ten Eyck P, Rubenstein LM, Snetselaar LG, Wahls TL. Association between improved metabolic risk factors and perceived fatigue during dietary intervention trial in relapsing-remitting multiple sclerosis: A secondary analysis of the WAVES trial. Front Neurol. 2023 Jan 19;13:1022728. doi: 10.3389/fneur.2022.1022728 PMID: 36742040; PMCID: PMC9892773.
[10]Azary S, Schreiner T, Graves J, Waldman A, Belman A, Guttman BW, Aaen G, Tillema JM, Mar S, Hart J, Ness J, Harris Y, Krupp L, Gorman M, Benson L, Rodriguez M, Chitnis T, Rose J, Barcellos LF, Lotze T, Carmichael SL, Roalstad S, Casper CT, Waubant E. Contribution of dietary intake to relapse rate in early paediatric multiple sclerosis. J Neurol Neurosurg Psychiatry. 2018 Jan;89(1):28-33. doi: 10.1136/jnnp-2017-315936 Epub 2017 Oct 9. PMID: 28993476; PMCID: PMC5732893.
[11] Lee JE, Titcomb TJ, Bisht B, Rubenstein LM, Louison R, Wahls TL. A Modified MCT-Based Ketogenic Diet Increases Plasma β-Hydroxybutyrate but Has Less Effect on Fatigue and Quality of Life in People with Multiple Sclerosis Compared to a Modified Paleolithic Diet: A Waitlist-Controlled, Randomized Pilot Study. J Am Coll Nutr. 2021 Jan;40(1):13-25. doi: 10.1080/07315724.2020.1734988 1734988. Epub 2020 Mar 26. PMID: 32213121; PMCID: PMC11833548.
[12] Irish AK, Erickson CM, Wahls TL, Snetselaar LG, Darling WG. Randomized control trial evaluation of a modified Paleolithic dietary intervention in the treatment of relapsing-remitting multiple sclerosis: a pilot study. Degener Neurol Neuromuscul Dis. 2017 Jan 4;7:1-18. doi: 10.2147/DNND.S116949 PMID: 30050374; PMCID: PMC6053098.
[13] Shemirani F, Titcomb TJ, Saxby SM, Eyck PT, Rubenstein LM, Hoth KF, Snetselaar LG, Wahls TL. Association of serum homocysteine, folate, and vitamin B12 and mood following the Swank and Wahls elimination dietary interventions in relapsing-remitting multiple sclerosis: Secondary analysis of the WAVES trial. Mult Scler Relat Disord. 2023 Jul;75:104743. doi: 10.1016/j.msard.2023.104743. Epub 2023 May 1. PMID: 37148578; PMCID: PMC11887414.
[14] Bahr LS, Bock M, Liebscher D, Bellmann-Strobl J, Franz L, Prüß A, Schumann D, Piper SK, Kessler CS, Steckhan N, Michalsen A, Paul F, Mähler A. Ketogenic diet and fasting diet as Nutritional Approaches in Multiple Sclerosis (NAMS): protocol of a randomized controlled study. Trials. 2020 Jan 2;21(1):3. doi: 10.1186/s13063-019-3928-9. PMID: 31898518; PMCID: PMC6941322.
[15] Lee JE, Titcomb TJ, Bisht B, Rubenstein LM, Louison R, Wahls TL. A Modified MCT-Based Ketogenic Diet Increases Plasma β-Hydroxybutyrate but Has Less Effect on Fatigue and Quality of Life in People with Multiple Sclerosis Compared to a Modified Paleolithic Diet: A Waitlist-Controlled, Randomized Pilot Study. J Am Coll Nutr. 2021 Jan;40(1):13-25. doi: 10.1080/07315724.2020.1734988.1734988. Epub 2020 Mar 26. PMID: 32213121; PMCID: PMC11833548.
[16] Bock M, Karber M, Kuhn H. Ketogenic diets attenuate cyclooxygenase and lipoxygenase gene expression in multiple sclerosis. EBioMedicine. 2018 Oct;36:293-303. doi: 10.1016/j.ebiom.2018.08.057 Epub 2018 Oct 3. PMID: 30292675; PMCID: PMC6197715.
[17] Storoni M, Plant GT. The Therapeutic Potential of the Ketogenic Diet in Treating Progressive Multiple Sclerosis. Mult Scler Int. 2015;2015:681289. doi: 10.1155/2015/681289 Epub 2015 Dec 29. PMID: 26839705; PMCID: PMC4709725.
[18] Chase E, Chen V, Martin K, Lane M, Wooliscroft L, Adams C, Rice J, Silbermann E, Hollen C, Fryman A, Purnell JQ, Vong C, Orban A, Horgan A, Khan A, Srikanth P, Yadav V. A low-fat diet improves fatigue in multiple sclerosis: Results from a randomized controlled trial. Mult Scler. 2023 Nov;29(13):1659-1675. doi: 10.1177/13524585231208330. PMID: 37941305; PMCID: PMC10655900.
[19] Rahmani F, Ghezzi L, Tosti V, Liu J, Song SK, Wu AT, Rajamanickam J, Obert KA, Benzinger TLS, Mittendorfer B, Piccio L, Raji CA. Twelve Weeks of Intermittent Caloric Restriction Diet Mitigates Neuroinflammation in Midlife Individuals with Multiple Sclerosis: A Pilot Study with Implications for Prevention of Alzheimer's Disease. J Alzheimers Dis. 2023;93(1):263-273. doi: 10.3233/JAD-221007 PMID: 37005885; PMCID: PMC10460547.
[20] Burton JM, Costello FE. Vitamin D in multiple sclerosis and central nervous system demyelinating disease--a review. J Neuroophthalmol. 2015 Jun;35(2):194-200. doi: 10.1097/WNO.0000000000000256 PMID: 25985434.
[21]Feige J, Moser T, Bieler L, Schwenker K, Hauer L, Sellner J. Vitamin D Supplementation in Multiple Sclerosis: A Critical Analysis of Potentials and Threats. Nutrients. 2020 Mar 16;12(3):783. doi: 10.3390/nu12030783. PMID: 32188044; PMCID: PMC7146466.
[22] Sangha A, Quon M, Pfeffer G, Orton SM. The Role of Vitamin D in Neuroprotection in Multiple Sclerosis: An Update. Nutrients. 2023 Jun 30;15(13):2978. doi: 10.3390/nu15132978. PMID: 37447304; PMCID: PMC10346708.
[23] Yeh WZ, Gresle M, Jokubaitis V, Stankovich J, van der Walt A, Butzkueven H. Immunoregulatory effects and therapeutic potential of vitamin D in multiple sclerosis. Br J Pharmacol. 2020 Sep;177(18):4113-4133. doi: 10.1111/bph.15201. Epub 2020 Aug 5. PMID: 32668009; PMCID: PMC7443468.
[24] Platero JL, Cuerda-Ballester M, Ibáñez V, Sancho D, Lopez-Rodríguez MM, Drehmer E, Ortí JER. The Impact of Coconut Oil and Epigallocatechin Gallate on the Levels of IL-6, Anxiety and Disability in Multiple Sclerosis Patients. Nutrients. 2020 Jan 23;12(2):305. doi: 10.3390/nu12020305 PMID: 31979305; PMCID: PMC7070654.
[25] Benlloch M, Cuerda Ballester M, Drehmer E, Platero JL, Carrera-Juliá S, López-Rodríguez MM, Ceron JJ, Tvarijonaviciute A, Navarro MÁ, Moreno ML, de la Rubia Ortí JE. Possible Reduction of Cardiac Risk after Supplementation with Epigallocatechin Gallate and Increase of Ketone Bodies in the Blood in Patients with Multiple Sclerosis. A Pilot Study. Nutrients. 2020 Dec 10;12(12):3792. doi: 10.3390/nu12123792 PMID: 33322022; PMCID: PMC7763038.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Anna Górowska, Julia Lenart, Natalia Janik, Zuzanna Wadowska, Julia Janowiak, Martyna Sobiś, Anna Bogacka, Nina Kiersznowska, Małgorzata Buchman, Barbara Miłek

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Stats
Number of views and downloads: 9
Number of citations: 0